13-Azaprostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor.

AUTOR(ES)

Le Breton, G C

RESUMO

A newly synthesized 13-aza derivative of prostanoic acid (13-APA) specifically inhibited human platelet aggregation induced by arachidonic acid, prostaglandin H2, or the stable endoperoxide analog (15S)-hydroxy-9 alpha,11 alpha-)epoxymethano)-prosta-5Z,13E-dienoic acid. 13-APA also inhibited [14C]serotonin release in response to arachidonic acid, ADP, or thrombin, but did not inhibit primary aggregation induced by ADP or thrombin. 13-APA completely blocked prostaglandin H2-induced aggregation in indomethacin-treated resuspended platelets but did not inhibit thromboxane synthesis. We therefore conclude that 13-APA acts as a direct antagonist of the platelet thromboxane/endoperoxide receptor.

Documentos Relacionados

• Elevated Thromboxane Levels in the Rat during Endotoxic Shock: PROTECTIVE EFFECTS OF IMIDAZOLE, 13-AZAPROSTANOIC ACID, OR ESSENTIAL FATTY ACID DEFICIENCY
• Inhibition of human platelet thromboxane synthetase by 9,11-azoprosta-5,13-dienoic acid.
• Resolution of prostaglandin endoperoxide synthase and thromboxane synthase of human platelets.
• Specific interaction of aurintricarboxylic acid with the human immunodeficiency virus/CD4 cell receptor.
• Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo.